In addition, PLTP, CETP, and LCAT’s plasma concentrations or activities have been included as outcome measures in other intervention trials (e.g., ClinicalTrials.gov identifiers NCT03948295, NCT00240305), further underscoring their recognized value to elucidate mechanisms that can correct dyslipidemia. This evidence concerns the gene CETP and metabolic syndrome.